Kabra Drugs quarterly results and financials

Kabra Drugs (BSE 524322)₹17.76+9.09%(9 Nov 2026 close)Pharmaceuticals

Key facts

In the Mar 2026 quarter (standalone), Kabra Drugs reported sales of ₹35.46 Cr and net profit of ₹1.07 Cr, up 167.5% year on year. For the year to Mar 2026, sales were ₹92.88 Cr and net profit ₹4.97 Cr.

Sales (Mar 2026): ₹35.46 Cr
Net profit (Mar 2026): ₹1.07 Cr
Sales (FY Mar 2026): ₹92.88 Cr
Net profit (FY Mar 2026): ₹4.97 Cr
EPS (Mar 2026): ₹0.46
Borrowings (Mar 2026): ₹0.56 Cr

Company filings, standalone accounts; latest reported quarter Mar 2026

Kabra Drugs quarterly results

₹ crore unless stated; each column is a quarter.

Kabra Drugs Quarterly results
	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Sales	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7.16	19.77	30.44	35.46
Expenses	0.11	0.14	0.10	0.38	0.54	0.41	0.52	0.25	7.66	17.73	28.00	34.06
Operating Profit	−0.11	−0.12	−0.10	−0.36	−0.54	−0.39	−0.52	−0.23	−0.51	2.03	2.42	1.33
OPM %	—	—	—	—	—	—	—	—	−7.3%	10.3%	8.0%	3.8%
Other Income	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.65	0.03	0.19	0.19	0.12
Interest	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.00	0.02	0.02	0.03
Profit before tax	−0.13	−0.14	−0.12	−0.38	−0.56	−0.41	−0.54	0.40	−0.51	2.22	2.61	1.43
Tax %	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	16.7%	1.5%	25.3%
Net Profit	−0.13	−0.14	−0.12	−0.38	−0.56	−0.41	−0.55	0.40	−0.51	1.85	2.58	1.07
EPS (Rs)	−0.28	−0.31	−0.26	−0.85	−1.26	−0.41	−0.55	0.17	−0.22	0.79	1.09	0.46

Kabra Drugs profit and loss

₹ crore unless stated; years end in March. TTM is the last four quarters.

Kabra Drugs Profit and loss
	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	9.60	7.62	1.82	−0.05	0.00	0.00	0.00	0.00	0.00	0.00	92.88	92.83
Expenses	9.15	7.16	2.83	0.10	0.04	0.14	0.17	0.36	0.75	1.73	87.40	87.45
Operating Profit	0.44	0.43	−1.02	−0.12	−0.04	−0.14	−0.17	−0.34	−0.73	−1.71	5.32	5.27
OPM %	4.7%	5.8%	−56.9%	—	−150.0%	—	—	−3,400.0%	—	—	5.7%	5.7%
Other Income	0.03	0.12	−0.95	0.02	0.03	0.00	0.00	0.02	0.00	0.65	0.50	0.53
Interest	0.17	0.16	0.24	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.00
Depreciation	0.25	0.25	0.15	0.04	0.04	0.04	0.02	0.00	0.00	0.02	0.08	0.07
Profit before tax	0.06	0.15	−2.37	−0.17	−0.07	−0.19	−0.20	−0.35	−0.75	−1.10	5.73	5.75
Tax %	40.0%	7.1%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	13.4%	—
Exceptional items	0.00	0.00	−1.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—
Net Profit	0.04	0.14	−2.37	−0.17	−0.07	−0.19	−0.20	−0.35	−0.75	−1.10	4.97	4.99
EPS (Rs)	0.08	0.31	−5.39	−0.37	−0.15	−0.42	−0.44	−0.78	−1.70	−0.47	2.10	2.12
Dividend payout %	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	—

Kabra Drugs balance sheet

₹ crore, at each year end.

Kabra Drugs Balance sheet
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	4.38	4.38	4.39	4.39	4.39	4.40	4.39	4.39	4.38	4.38	23.70	23.68
Reserves	−1.79	−1.77	−1.84	−4.19	−4.36	−4.41	−4.60	−4.78	−5.13	−3.32	0.96	5.92
Borrowings	2.80	2.38	1.80	0.69	0.66	0.65	0.89	1.03	1.37	1.70	0.43	0.56
Other Liabilities	3.14	4.17	2.04	0.81	0.79	0.79	0.72	0.10	0.07	1.80	0.14	56.06
Total Liabilities	8.53	9.16	6.39	1.70	1.48	1.43	1.40	0.74	0.69	4.56	25.23	86.22
Fixed Assets	2.79	2.74	2.49	0.12	0.09	0.05	0.02	0.00	0.00	0.00	0.05	0.85
CWIP	0.09	0.20	0.20	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Investments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Assets	5.65	6.22	3.70	1.58	1.39	1.38	1.38	0.74	0.69	4.56	25.18	85.37
Inventories	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Trade receivables	3.99	4.99	2.99	0.99	0.99	0.99	0.99	0.99	0.99	0.99	0.99	70.93
Cash & equivalents	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.99	20.96	10.99
Total Assets	8.53	9.16	6.39	1.70	1.48	1.43	1.40	0.74	0.69	4.56	25.23	86.22

Kabra Drugs cash flow

₹ crore, for each year.

Kabra Drugs Cash flow
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from operating activity	−0.23	0.29	0.32	−0.13	−0.19	−0.06	−0.26	−0.14	−0.36	−0.22	−4.72	−9.48
Cash from investing activity	−0.19	−0.28	0.00	1.49	0.06	0.05	0.00	0.00	0.00	0.00	−0.04	−1.35
Cash from financing activity	0.59	−0.28	−0.33	−1.36	0.00	−0.03	0.26	0.14	0.37	2.89	23.41	0.13
Net cash flow	0.15	−0.27	0.00	0.03	−0.09	0.00	0.00	0.00	0.00	2.66	18.62	−10.71
Capex	0.20	0.30	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.04	0.71
Free cash flow	−0.42	−0.02	0.30	1.37	−0.17	−0.03	−0.24	−0.12	−0.34	−0.20	−4.75	−10.15
CFO / OP %	−38.0%	67.1%	73.1%	10.0%	138.1%	100.1%	167.1%	72.1%	100.1%	28.1%	274.1%	−173.0%

Kabra Drugs ratios

Working-capital days and returns, by year.

Kabra Drugs Ratios
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor days	198	204	141	254	−11,406	—	—	—	—	—	—	279
Inventory days	26	16	17	0	0	—	—	—	—	—	—	0
Days payable	130	140	97	—	—	—	—	—	—	—	—	—
Cash conversion cycle	94	80	61	254	−11,406	—	—	—	—	—	—	279
Working capital days	86	70	34	−28	−912	—	—	—	—	—	—	66
ROCE %	4.4%	4.4%	6.6%	−44.2%	−18.8%	−9.1%	−27.5%	−28.6%	−52.7%	−43.1%	−7.8%	20.8%

Kabra Drugs: frequently asked questions

What are the latest quarterly results of Kabra Drugs?

For the Mar 2026 quarter, Kabra Drugs reported sales of ₹35.46 Cr and net profit of ₹1.07 Cr, up 167.5% year on year. The operating margin was 3.8%.

What is the annual revenue of Kabra Drugs?

Kabra Drugs' sales for the year to Mar 2026 were ₹92.88 Cr; over the last twelve months they were ₹92.83 Cr.

What is the net profit of Kabra Drugs?

Net profit for the year to Mar 2026 was ₹4.97 Cr, and ₹4.99 Cr over the last twelve months. Earnings per share over the same trailing period were ₹2.12.

How much debt does Kabra Drugs have?

Kabra Drugs reported borrowings of ₹0.56 Cr at Mar 2026, against cash and equivalents of ₹10.99 Cr.

What is the free cash flow of Kabra Drugs?

Cash from operations was −₹9.48 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹10.15 Cr.

Loading…